Smartcella obtains Swedish approval for GMP manufacturing and quality control testing of cell therapies

Cell and gene therapy company Smartcella,  through its business unit ProCella,  announced it has been granted manufacturing authorization as well as Good Manufacturing Practice (GMP) certification from the Swedish Medicinal Product Agency, allowing the company to begin clinical production of cell-based therapies for clinical studies.
The facility will be available both for the manufacturing of internal therapeutic developments and for third-party manufacturing, for pre-clinical and clinical development phases.